Neogenomics Inc (NEO) · Oct 28, 2026 · Earnings
Beat — Adjusted diluted EPS $0.07 vs ~$0.06 consensus; revenue $209.3M vs ~$206.7M consensus
NeoGenomics earnings beat Q3 revenue and adjusted EPS expectations, while FY26 revenue and EBITDA guidance moved higher.
NeoGenomics is shifting toward higher-value oncology testing—especially next-generation sequencing and molecular residual disease assays—while trying to improve margins through payer expansion, digital infrastructure, and operating efficiency. That strategy is showing up in the mix: the company’s own 2026 priorities emphasize NGS, RaDaR ST, community oncology expansion, and scalable operations.
The quarter cleared published expectations, but not by a wide margin. Revenue was $209.3 million versus consensus of approximately $206.7 million, while adjusted diluted EPS was $0.07 versus roughly $0.06 expected. Revenue growth was supported more by pricing and mix than by volume: clinical test volume rose 2%, while average revenue per test increased 11% to $530.
| Metric | Q3 2026 | Q3 2025 | Comparison / expectation |
|---|---|---|---|
| Revenue | $209.3M | $187.8M | +11.4%; vs ~$206.7M consensus |
| GAAP net loss | $(7.5)M | $(27.1)M | Loss narrowed 72% |
| Adjusted EBITDA | $18.7M | $12.2M | +53% |
| Adjusted diluted EPS | $0.07 | $0.03 | vs ~$0.06 consensus |
| Clinical test volume | 367,279 | 360,774 | +1.8% |
| Average revenue per test | $530 | $476 | +11.3% |
The more important improvement is operating leverage. Gross margin expanded to 46.2% from 42.8%, and adjusted EBITDA rose 53% to $18.7 million despite only 11% revenue growth. The business is therefore progressing toward its stated goal of growing faster through higher-value tests rather than simply processing more samples.
Full-year guidance moved up, although the surprise was partly disclosed already. Revenue guidance increased from $802–806 million to $807–809 million, and adjusted EBITDA guidance rose from $56–58 million to approximately $60 million. The revenue range had been effectively previewed by the company’s October 5 preliminary update, so the new information is mainly the confirmed quarterly beat and the modestly better profitability outlook.
Cash generation remains the constraint behind the improvement story. NeoGenomics produced only $2.9 million of operating cash flow in the first nine months while spending $25.0 million on property and equipment, and cash declined to $139.3 million from $159.6 million at year-end. The earnings improvement is real, but it has not yet translated into substantial free cash generation.
Bottom line: This was a genuine earnings beat with better margins and a modest guidance lift, strengthening the case that NeoGenomics’ NGS-led mix shift is working. The signal is positive, but the revenue upside was partly known and cash conversion is still unfinished business.
CEO succession effective January 4, 2027
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!